Amit Gandhi, M.Pharm, Ph.D.’s Post

An excellent 𝑵𝒂𝒕𝒖𝒓𝒆 𝑪𝒐𝒎𝒎𝒖𝒏𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔 paper by Youya Nakazawa et al. describing yet another innovative ADC structure. In the paper the authors show preclinical efficacy in a pancreatic cancer model of an ADC composed of a BET protein-degrader 'warhead' conjugated to an anti-CEACAM6 antibody. https://lnkd.in/eUK_P294

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer EMBO https://lnkd.in/gyfkJCuc

#CDK4/6 inhibitors show anticancer activity in certain human malignancies, but their application to other tumor types and intrinsic resistance mechanisms are still unclear. #MYC amplification confers resistance to CDK4/6 inhibitors in bladder, prostate, and #breastcancer cancer cells, and a compound that degrades MYC, A80.2HCl, restores sensitivity of MYC high-expressing cancer cells to CDK4/6i. #cancerresearch #drugdiscovery https://lnkd.in/eMuJf9-5

Carnitine reverts in vitro the strong antimelanoma effects of miconazole. In addition, expression of genes related to carnitine function is strongly altered in melanoma patients. Please carefully evaluate carnitine supplementation under cancer therapy. See the recently published study in IJMS Open access https://lnkd.in/dw44RZkq

I'm excited to share my latest article published on Pharmacy Times, where I delve into the journey and potential of PI3K inhibitors in breast cancer therapy. 💗 ✨ These targeted therapies represent a significant advancement, especially for patients with PIK3CA mutations, offering new hope in managing this complex disease. 🔍 Read the article here: Pharmacy Times - The Evolution of PI3K Inhibitors in Breast Cancer Treatment (https://lnkd.in/emvfw7VP)

In a prospective study from Fudan University Shanghai Cancer Center, involving patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone, one-third of patients showed interlesional response heterogeneity (ILRH) on PET/CT. Patients with hetero-responding disease had significantly different PFS compared to responding and non-responding groups. ILRH on both baseline and week-13 PSMA and FDG PET/CT was found to strongly associate with conventional PFS. #mCRPC #prostatecancer #abiraterone #PETCT #ILRH #PSMA #PFS #cancerresearch https://lnkd.in/ddcimiab

#Saruparib Saruparib, a first-in-class PARP1-­selective inhibitor, was reported to have favorable safety and anticancer activity in heavily pretreated patients with breast cancer harboring homologous recombination–repair mutations, according to the results of the phase I/II PETRA study presented at the American Association for Cancer Research Annual Meeting 2024. Moreover, the safety profile of this new drug appears to allow patients with advanced solid tumors to stay on treatment longer with increased drug exposure, compared with currently approved PARP inhibitors, which target both PARP1 and PARP2. #AACR2024 #PARPinhibitor #Breastcancer #Oncology #Innovation

EML4-ALK is an oncogenic fusion protein that drives progression of ~5% of non-small cell lung cancer cases! Differential breakpoints in EML4 give rise to distinct splice variants with variant 3 (V3) being the most aggressive and resistant variant to targeted therapeutics. Check out this new paper from our lab suggesting that the Eg5 motor protein is a downstream component of a new pathway discovered in patients with EML4-ALK V3 thus, identifying a possible novel target for future treatments! https://lnkd.in/gDWTyDWt

Excited to share the publication of our systematic review “Targeting BCL-2 Family Proteins Using BH3 Mimetic Drugs for Cancer Therapy: A Systematic Review of Randomized Clinical Trials.” This study rigorously analyzes clinical trial data to assess the safety and effectiveness BH3 mimetic drugs in malignancies. A big thank you to Mohammad Ashrafuzzaman and Fatimah Alharbi for their support and contribution. Evidence-based research is essential in advancing medicine and patient outcomes. https://lnkd.in/dAzyxb_9 #Science #Medicine #Cancer #Oncology #ClinicalTrials

Anti- CEACAM6 antibody+ BET protein degrader conjugate inhibits tumour growth in pancreatic cancer models. https://lnkd.in/g43BaqPm